|
1.
|
Cappuzzo F, Ligorio C, Jänne PA, et al:
Prospective study of gefitinib in epidermal growth factor receptor
fluorescence in situ hybridization-positive/phospho-Akt-positive or
never smoker patients with advanced non-small-cell lung cancer: the
ONCOBELL trial. J Clin Oncol. 25:2248–2255. 2007. View Article : Google Scholar
|
|
2.
|
Lin CC and Yang CH: Epidermal growth
factor receptor tyrosine kinase inhibitors in elderly or poor
performance status patients with advanced non-small cell lung
cancer. Target Oncol. 4:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Chang BW and Saif MW: Combining epidermal
growth factor receptor inhibitors and radiation therapy in
pancreatic cancer: small step or giant leap? JOP. 10:231–236.
2009.PubMed/NCBI
|
|
4.
|
Magné N, Chargari C, Castadot P, et al:
The efficacy and toxicity of EGFR in the settings of radiotherapy:
focus on published clinical trials. Eur J Cancer. 44:2133–2143.
2008.PubMed/NCBI
|
|
5.
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
6.
|
Wiffen P, Mitchell M, Snelling M and
Stoner N: Oxford Handbook of Clinical Pharmacy. 2nd edition. Oxford
University Press; New York: 2007
|
|
7.
|
Yoneda S: Outpatient chemotherapy for lung
cancer. Gan To Kagaku Ryoho. 34:533–537. 2007.(In Japanese).
|
|
8.
|
Chang A, Parikh P, Thongprasert S, et al:
Gefitinib (IRESSA) in patients of Asian origin with refractory
advanced non-small cell lung cancer: subset analysis from the ISEL
study. J Thorac Oncol. 1:847–855. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wu YL, Yang JJ, Lin JY, et al: Gefitinib
target treatment in non-small cell lung cancer. Chin J Tuber Respir
Dis. 30:98–102. 2007.(In Chinese).
|
|
10.
|
Gao Z, Han B, Wang H, et al: Clinical
observation of gefitinib as a first-line therapy in sixty-eight
patients with advanced NSCLC. Oncol Lett. 3:1064–1068.
2012.PubMed/NCBI
|
|
11.
|
Gandara DR, Davies AM, Gautschi O, et al:
Epidermal growth factor receptor inhibitors plus chemotherapy in
non-small-cell lung cancer: biologic rationale for combination
strategies. Clin Lung Cancer. 2:S61–S67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Tanaka T, Munshi A, Brooks C, et al:
Gefitinib radiosensitizes non-small cell lung cancer cells by
suppressing cellular DNA repair capacity. Clin Cancer Res.
14:1266–1273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Zhuang HQ, Sun J, Yuan ZY, et al:
Radiosensitizing effects of gefitinib at different administration
times in vitro. Cancer Sci. 100:1520–1525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Stinchcombe TE, Morris DE, Lee CB, et al:
Induction chemo-therapy with carboplatin, irinotecan, and
paclitaxel followed by high dose three-dimension conformal thoracic
radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and
gefitinib in unresectable stage IIIA and stage IIIB non-small cell
lung cancer. J Thorac Oncol. 3:250–257. 2008.
|
|
15.
|
Fischer JR, Geiger D, Haffner UJ and Lahm
H: Successful individualized and targeted therapy of an NSCLC
patient with gefitinib based on a predictive assessment of the
EGF-receptor mutation status. Pneumologie. 61:264–269. 2007.(In
German).
|
|
16.
|
Yoshida K, Yatabe Y, Park JY, et al:
Prospective validation for prediction of gefitinib sensitivity by
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer. J Thorac Oncol. 2:22–28. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fukuoka M, Wu Y, Thongprasert S, et al:
Biomarker analyses from a phase III, randomized, open-label,
first-line study of gefitinib versus carboplatin/paclitaxel in
clinically selected patients with advanced non-small cell lung
cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011.
View Article : Google Scholar
|
|
18.
|
Zhong W, Wang M, Li L, et al: EGFR gene
mutation statuses in advanced non-small cell lung cancer patients
and their influence on effect of gefitinib. Chin J Lung Cancer.
15:513–520. 2012.(In Chinese).
|
|
19.
|
Maemondo M, Minegishi Y, Inoue A, et al:
First-line gefitinib in patients aged 75 or older with advanced
non-small cell lung cancer harboring epidermal growth factor
receptor mutations: NEJ 003 study. J Thorac Oncol. 7:1417–1422.
2012. View Article : Google Scholar : PubMed/NCBI
|
